Since launching in 2018, we have supported 20 fledgling life-science companies. Each cohort brings with it a diverse set of skills, expertise and experience, but they all share a deep passion for their science or technology and a desire to make a difference to the lives of tomorrow’s patients. We keep in touch with all our cohort companies and are proud to continue to support and follow their progress.
Meet the Last Cohort
Our 2023/24 cohort, Aila Biotech, BugBiome, CytoCalx, Gigabiome, Matrix Bio and Neurothread Diagnostics completed their entrepreneurial journey with us earlier this year. Find out a little more about them here...
"Accelerate@Babraham has introduced us to a whole host of experts who have been incredibly helpful. One of the key value-adds of being on the Campus is the network, the eco-sphere. It’s enabled us to develop four collaborations, one patent, one investment and two grants.”
Matthew Cummings, Co-Founder and CEO of CC Bio
“Being on the Accelerate@Babraham programme has helped to shape our business plan and discover new routes to market and we have moved forward faster because of it.”
Daniel Ives, Founder and CEO of ShiftBioscience
“One of the most exciting things about the Accelerate@Babraham programme is the huge number of phenomenal people we’ve met both in the Cambridge eco-system and beyond who have supported and mentored us. This, in addition to access to well-equipped lab facilities and equipment, has helped us to leverage our idea into a development discovery programme over five months”.
Tim Newton, Co-Founder and CEO of Reflection Therapeutics
“Being from an academic background, I have really benefitted from all the business advice and mentorship from the experts whilst on the Accelerate@Babraham programme. I would recommend it to start-ups; it’s a really brilliant programme with access to advice, lab and office space, and it really is fun!”
Marloes Tijssen, CEO of TropoFour Therapeutics
“I really recommend the Accelerate@Babraham programme as it has facilitated a great acceleration of our company. Our visibility has improved within the UK eco-system which has allowed us to attract investors and advisors and build trust with suppliers which is enabling us to progress on our journey.”
Antoine Espinet, Founder and CEO of MicrofluidX
Meet the Alumni
Therapeutics is our thing…but over the last four years our cohort companies have also come to us with strong foundational ideas across the fields of diagnostics, medical devices, and machine learning and AI. In each case we’ve been able to support them with very specific expert and investor introductions as well as help them refine their thinking; enabling them to take their science and technology further - equipping them for success.